Market capitalization | $2.58b |
Enterprise Value | $2.79b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 4.98 |
P/S ratio (TTM) P/S ratio | 4.60 |
P/B ratio (TTM) P/B ratio | 35.89 |
Revenue growth (TTM) Revenue growth | 18.45% |
Revenue (TTM) Revenue | $560.03m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
12 Analysts have issued a iRhythm Technologies, Inc. forecast:
12 Analysts have issued a iRhythm Technologies, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 560 560 |
18%
18%
|
|
Gross Profit | 380 380 |
18%
18%
|
|
EBITDA | -81 -81 |
6%
6%
|
EBIT (Operating Income) EBIT | -107 -107 |
0%
0%
|
Net Profit | -151 -151 |
44%
44%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
iRhythm Technologies, Inc. engages in the development of monitoring and diagnostic solutions for detection of cardiac arrhythmias. It offers Zio XT, is a wearable patch-based biosensor, continuously records and stores ECG data from every patient heartbeat for up to 14 consecutive days; and Zio AT, also provides ECG data but also provides physicians with actionable notifications during the wear period. The company was founded by Uday N. Kumar in September 2006 and is headquartered in San Francisco, CA.
Head office | United States |
CEO | Quentin Blackford |
Employees | 2,000 |
Founded | 2006 |
Website | www.irhythmtech.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.